BioXcel Therapeutics Inc (NASDAQ:BTAI) shares, rose in value on Thursday, April 25, with the stock price down by -4.43% to the previous day’s close as strong demand from buyers drove the stock to $2.59.
Actively observing the price movement in the recent trading, the stock is buoying the session at $2.71. Referring to stock’s 52-week performance, its high was $29.56, and the low was $1.91. On the whole, BTAI has fluctuated by -9.44% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 2.65M, with a low estimate of 400k and a high estimate of 500k. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 450k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that BTAI’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of BTAI currently trading nearly -4.99% and -10.75% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.70, while the 7-day volatility ratio is showing 9.06% which for the 30-day chart, stands at 6.72%. Furthermore, BioXcel Therapeutics Inc (BTAI)’s beta value is 0.40, and its average true range (ATR) is 0.21.
A comparison of BioXcel Therapeutics Inc (BTAI) with its peers suggests the former has fared considerably weaker in the market. BTAI showed an intraday change of -4.43% in today’s session so far, and over the past year, it shrunk by -87.67%%.
Data on historical trading for BioXcel Therapeutics Inc (NASDAQ:BTAI) indicates that the trading volumes over the past 3 months, they’ve averaged 1.54 million. According to company’s latest data on outstanding shares, there are 29.93 million shares outstanding.
Nearly 26.96% of BioXcel Therapeutics Inc’s shares belong to company insiders and institutional investors own 25.47% of the company’s shares. The stock has fallen by -12.21% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the BTAI stock heading into the next quarter.
